Indication: BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.Dosage & Administration:BarifTM is recommended at 40 mg or 80 mg once daily. The recommended starting dos..
Indication: BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.Dosage & Administration:BarifTM is recommended at 40 mg or 80 mg once daily. The recommended starting dos..
Febuxostat INN 40mg & 80mg/tablet.40mg x 30's pack: 360.00 MRP10 Pcs Tablet: 120.00 MRP..Indication:BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.Dosage & Administration:Bar..
Febuxostat INN 40mg & 80mg/tablet.80mg x 10'sIndication:BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.Dosage & Administration:BarifTM is recommended at 40 mg or 80 mg o..
Febuxostat INN 40mg & 80mg/tablet.40mg x 30's Indication:BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.Dosage & Administration:BarifTM is recommended at 40 mg or 8..
Febustat 40 mg TabDescriptionFebustat is FDA approved non-purine, selective inhibitor of xanthine oxidase approved for the chronic management of hyperuricemia in patients with gout. It is not recommended for asymptomatic or secondary hyperuricemia, nor is it indicated for treatment of acute gout. Fe..
Goustat 40 mg TabletDescriptionGOUSTAT (Febuxostat) is a potent non-purine, selective inhibitor of xanthine oxidase. GOUSTAT lowers serum uric acid levels by blocking xanthine oxidase, the enzyme responsible for uric acids production. Xanthine oxidase breaks down hypoxanthine (a natural-occurring pu..